Bankrupt 23andMe Just Sold Off All Your DNA Data

Your DNA results in – 100 percent of the manufacturer of pharmaceutical products.

The American Biotech Company Regeneron Pharmaceuticals today announced that it buys 23andme, a bankrupt consumer company that sold the DNA groups wandering at home. Regeneron will pay $ 256 million in cash to gain “each” of 23ndme assets, including the huge biological bank, which includes about 15 million samples and genetic data.

Simply put, the genetic information of millions is now in the hands of the drug maker who seeks to extract it to make new treatments, for each Washington PostWhich can be a nightmare of data privacy in making.

The aforementioned samples were presented by Tayeb Khater by consumers in exchange for 23andme to decode their DNA, a process that provided people with a wonderful glimpse of their genetic formulas and family history. This type of biometric data is both largely valuable and widely studded after that, so when 23andme was financially in the abdomen, genetic information caught her attention quickly as a profitable origin. This awareness immediately raised concerns among data privacy experts, who warned that selling 23andme data means that the genetic information of customers, not to mention information about relatives close to customers, was ready for the highest bid.

In her press statement, Regeneron said she “intends” to honor the current privacy practices of 23andme. Meanwhile, the founder of Regeneron Coftern and its president, George Yankopoulos, issued a statement focusing on “a deep experience with data management on a large scale, after working with collaborators all over the world to connect the sequence of the DNA specified of nearly three million participants to approve electronic health records, safely and safely enabling future medical progress.”

“We believe that we can help 23andme to achieve its mission and build on it to help those interested in learning about their DNA and how to improve their personal health,” Yancopoulos’s statement continued, while strengthening Regeneron’s efforts to use genetic research on a large scale to improve the way in which society is treated in general. “

However, Regeneron is not just a search laboratory. It sells the medications that it creates, and the genotan data obtained from historical sale must eventually lead to the creation of medicines, as they raise questions about whether consumers will be compensated for their contributions.

“The deal increases the value of work and enables the 23DME mission to live, while maintaining critical protection on the customer’s privacy, choice and approval regarding their genetic data.”

More about 23andme: 23andme sells all your data, in the largest sale of generations in history